UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

'All In One' SARS-CoV-2 variant recognition platform: Machine learning-enabled point of care diagnostics

Biosensors and bioelectronics. X, 2022-05, Vol.10, p.100105-100105, Article 100105

2022

Volltextzugriff (PDF)

Smoke-free Ege: An attempt for an integrative prevention strategy for tobacco control at a University setting

Tobacco induced diseases, 2018-10, Vol.16 (3)

2018

Volltextzugriff (PDF)

PD09-1-1. KEYVIBE-006 : Randomized, Phase 3 Study of MK-7684A Plus cCRT for Unresectable, Stage III NSCLC

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.729-729

2022

Volltextzugriff (PDF)

Postoperative Mediastinal Chyloma Following Lobectomy Imitating Lymph Node Metastasis

Chest, 2012-10, Vol.142 (4), p.615A-615B

2012

Volltextzugriff (PDF)

P2.06-012 Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1076-S1077

2017

Volltextzugriff (PDF)

P2.06-012 Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer: Topic: Phase II + NK

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1076-S1077

2017

Volltextzugriff (PDF)

An unexpected cause of hemoptysis: endobronchial lipomatous hamartoma

Medicinski arhiv, 2014, Vol.68 (1), p.65-66

2014

Volltextzugriff (PDF)

Clinical Characteristics of Patients with Bronchioloalveolar Carcinoma: A Retrospective Study of 44 Cases

Asian Pacific journal of cancer prevention : APJCP, 2013, Vol.14 (7), p.4365-4368

2013

Volltextzugriff (PDF)

Akciğer Kanserlerinde Likid Biyopsinin Prognostik ve Prediktif Rolü

Göksel, Tuncay

2023

Volltextzugriff (PDF)

Erratum to “High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients” [Lung Cancer 62 (2008) 326–333]

Lung cancer (Amsterdam, Netherlands), 2009-07, Vol.65 (1), p.128-128

2009

Volltextzugriff (PDF)

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaieve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

European journal of cancer (1990), 2009-09, Vol.45 (13), p.2298-2303

2009

Volltextzugriff (PDF)

Immunotherapy and multidisciplinary approach to treatment in lung cancer

Tüberküloz ve toraks, 2020-03, Vol.68 (1), p.66-75

2020

Volltextzugriff (PDF)

S9-1 REVEL : Ramucirumab-Docetaxel vs Placebo-Docetaxel in Second-line Stage IV Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer, 2014-10, Vol.54 (5), p.285-285

2014

Volltextzugriff (PDF)

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9025-9025

2018

Volltextzugriff (PDF)

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8055-8055

2015

Volltextzugriff (PDF)

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

Journal of clinical oncology, 2014-06, Vol.32 (18_suppl), p.LBA8006-LBA8006

2014

Volltextzugriff (PDF)

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.LBA8006-LBA8006

2014

Volltextzugriff (PDF)

Hemophagocytic syndrome due to lung infection: a case report

Tüberküloz ve toraks, 2011-01, Vol.59 (4), p.374-379

2011

Volltextzugriff (PDF)

Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer

Tüberküloz ve toraks, 2008, Vol.56 (1), p.74-80

2008

Volltextzugriff (PDF)

İleri evre küçük hücreli dışı akciğer karsinomunda sisplatin-etoposid ile mitomisin-ifosfamid-sisplatin kombinasyonlarının karşılaştırılması

Tüberküloz ve toraks, 2006, Vol.54 (2), p.161-167

2006

Volltextzugriff (PDF)

Akciğer kanserli olgularda gelişen alt solunum yolu infeksiyonları

Toraks Dergisi, 2006, Vol.7 (2), p.79-83

2006

Volltextzugriff (PDF)

İzmir ili lise öğrencilerinin sigara alışkanlığını etkileyen faktörler

Toraks Dergisi, 2001, Vol.2 (3), p.49-53

2001

Volltextzugriff (PDF)

Malign plevral efüzyonlarda intraplevral bleomisin tedavisi

Toraks Dergisi, 2000, Vol.1 (3), p.35-39

2000

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Aktive Filter

KollektionSAGE Journals Online

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)
Dissertationen
(1)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Respiratory Tract Diseases
(8)
Solunum Yolu Hastalıkları
(8)
Retrospective Studies
(6)
Geriyedönük Çalışma
(5)
Akciğer Neoplazmları
(3)
Carcinoma, Non-Small-Cell Lung
(3)
Humans
(3)
Karsinom, Küçük Hücreli Dışı Akciğer
(3)
Lung Neoplasms
(3)
Male
(3)
Neoplasms
(3)
Neoplazmlar
(3)
Smoking
(3)
Terapötik
(3)
Therapeutics
(3)
Aged
(2)
Akciğer Hastalığı, Kronik Obstrüktif
(2)
Araştırma Teknikleri
(2)
Female
(2)
Investigative Techniques
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

'All In One' SARS-CoV-2 variant recognition platform: Machine learning-enabled point of care diagnostics

Smoke-free Ege: An attempt for an integrative prevention strategy for tobacco control at a University setting

PD09-1-1. KEYVIBE-006 : Randomized, Phase 3 Study of MK-7684A Plus cCRT for Unresectable, Stage III NSCLC

Postoperative Mediastinal Chyloma Following Lobectomy Imitating Lymph Node Metastasis

P2.06-012 Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer

P2.06-012 Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer: Topic: Phase II + NK

An unexpected cause of hemoptysis: endobronchial lipomatous hamartoma

Clinical Characteristics of Patients with Bronchioloalveolar Carcinoma: A Retrospective Study of 44 Cases

Akciğer Kanserlerinde Likid Biyopsinin Prognostik ve Prediktif Rolü

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Erratum to “High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients” [Lung Cancer 62 (2008) 326–333]

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaieve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Immunotherapy and multidisciplinary approach to treatment in lung cancer

S9-1 REVEL : Ramucirumab-Docetaxel vs Placebo-Docetaxel in Second-line Stage IV Non-Small Cell Lung Cancer

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC)

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy

Hemophagocytic syndrome due to lung infection: a case report

Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer

İleri evre küçük hücreli dışı akciğer karsinomunda sisplatin-etoposid ile mitomisin-ifosfamid-sisplatin kombinasyonlarının karşılaştırılması

Akciğer kanserli olgularda gelişen alt solunum yolu infeksiyonları

İzmir ili lise öğrencilerinin sigara alışkanlığını etkileyen faktörler

Malign plevral efüzyonlarda intraplevral bleomisin tedavisi

Aktive Filter

Suchergebnisse filtern